Article:ENT and mucopolysaccharidoses (6238253)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at https://www.wikidata.org/wiki/Q59340090. Its title is ENT and mucopolysaccharidoses and the publication date was 2018-11-16. The initial author is Pier Marco Bianchi.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.



Converted JATS paper:

Journal Information

Title: Italian Journal of Pediatrics

ENT and mucopolysaccharidoses

  • Pier Marco Bianchi
  • Renato Gaini
  • Silvano Vitale

Publication date (epub): 11/2018

Publication date (pmc-release): 11/2018

Publication date (collection): /2018

Abstract

The mucopolysaccharidoses (MPS) are a heterogeneous group of inherited metabolic disorders, each associated with a deficiency in one of the enzymes involved in glycosaminoglycan (GAG) catabolism. Over time, GAGs accumulate in cells and tissues causing progressive damage, a variety of multi-organ clinical manifestations, and premature death. Ear, nose, and throat (ENT) disorders affect more than 90% of MPS patients and appear in the early stage of MPS; also reported are recurrent otitis media and persistent otitis media with effusion, macroglossia, adenotonsillar hypertrophy, nasal obstruction, obstructive sleep apnoea syndrome (OSAS), hearing loss, and progressive respiratory disorders. Undiagnosed MPS patients are frequently referred to otolaryngologists before the diagnosis of MPS is confirmed. Otolaryngologists thus have an early opportunity to recognize MPS and they can play an increasingly integral role in the multidisciplinary approach to the diagnosis and management of many children with MPS. The ENT commitment is therefore to suspect MPS when non-specific ENT pathologies are associated with repeated surgical treatments, unexplainable worsening of diseases despite correct treatment, and with signs, symptoms, and pathological conditions such as hepatomegaly, inguinal hernia, macrocephaly, macroglossia, coarse facial features, hydrocephalous, joint stiffness, bone deformities, valvular cardiomyopathy, carpal tunnel syndrome, and posture and visual disorders.

Paper

Background

Why is the paediatric otolaryngologist involved and what is their role in mucopolysaccharidosis?

Ear, nose, and throat (ENT) manifestations in mucopolysaccharidosis (MPS) are due to the accumulation of glycosaminoglycans (GAGs) in the head and neck region. The ENT manifestations are very common and include protruding or depressed frontal bone, a depressed nasal bridge, wide nasal alae, thick lips, angled and hypoplastic mandible (micrognathia), macroglossia, distorted teeth, gingival hypertrophy, and also restriction of the mouth opening, adenotonsillary hypertrophy, and thickening of soft tissues in the laryngopharynx. Head and neck disorders affect more than 90% of MPS patients [[1], [2]]. The median age of a first ENT visit is 4.2 years, generally prior to MPS diagnosis [[3][9]]. Symptoms such as “noisy breathing”, sleep apnoea, frequent respiratory and ear infections, chronic nasal discharge, and enlargement of the tongue, tonsils, and adenoids may often predate a definitive MPS diagnosis by several years, particularly in patients with an attenuated phenotype. MPS, owing to the non-specific nature of the early symptoms, is therefore often unrecognized [[10], [11]]. The early recognition and prompt diagnosis of MPS disorders is crucial. Early treatment considerably improves patient outcomes during long-term therapy and is crucial to slow disease progression before irreversible damage occurs. Undiagnosed patients are frequently referred to otolaryngologists for ENT manifestations; these specialists thus have an early opportunity to recognize MPS. Therefore, the otolaryngologist is an essential member of the care management team for the disorders of MPS patients and they are in a prime position to initiate diagnostic work-up and referral for definitive testing [[9]].

ENT disease in MPS can be schematically divided into respiratory disorders and otological or hearing problems.

In summary, otolaryngologists often see as yet undiagnosed MPS patients. Their careful history collection and clinical evaluation may play an important role in the diagnosis and management plan.

What are the respiratory disorders in MPS?

Respiratory disorders occur in all type of MPS. Airway problems result from a combination of tissue storage of GAGs that produce a distortion of airway anatomy and function [[10], [12][16]]. Affected individuals classically have a number of anatomical features predisposing to airway dysfunction [[17]]. Progressive airway damage develops, often involving multiple levels within the upper respiratory tract, secondary to the progressive deposition of GAGs within the airway [[18]], at any level from the “lips to lungs” [[19]]. Airway problems include obstructive sleep apnoea (OSA), frequent respiratory infections, adenoid (Fig. 1) and tonsillar hypertrophy (Fig. 2), irregular nasal septum, turbinate hypertrophy, macroglossia (Fig. 3), thickened pharyngeal wall, laryngeal abnormalities, tracheomalacia, tracheal stenosis and short neck, dyspnoea, restricted joint mobility, skeletal abnormalities, and increased mucus secretions in the upper and lower airways [[20][24]]. Chronic rhinosinusitis and chronic otitis media may occur and produce hearing impairment [[10], [12]]. In extreme cases, excessive tissue on the arytenoid cartilages and aryepiglottic folds can prolapse into the laryngeal inlet causing stridor and airway obstruction [[24]]. Furthermore, hepatosplenomegaly may limit diaphragmatic excursion, and interstitial pulmonary GAG deposits may result in a diffusion defect [[13]]. Thickened and copious secretions throughout the upper and lower respiratory tracts are also commonly found and there is a tendency for frequent upper and lower respiratory tract infections. Recurrent throat and ear infections are present in more than 50% of patients [[25]]. However, due to the low number of patients, no conclusions can be made regarding the prevalence and severity of respiratory problems for each MPS type [[18]]. Initially, obstructive symptoms are more pronounced in the upper airway; tracheobronchial manifestations occur later. The respiratory involvement is usually progressive and can result in morbidity and mortality early in childhood [[10], [26]].Fig. 1

Adenoid hypertrophy

Fig. 2

Tonsillar hypertrophy

Fig. 3

Macroglossia and typical facies

The respiratory disorders in MPS can be divided into airway abnormalities (extrathoracic and intrathoracic), and alterations in respiratory and sleeping mechanics [[18]].

Extrathoracic anatomical abnormalities, including abnormal cervical vertebrae, a short neck, a relatively high epiglottis, deep cranial fossa narrowing the nasopharynx, a hypoplastic mandible with a short ramus, temporomandibular joint ankylosis, a small thoracic cage, frequently complicated by kyphoscoliosis [[13], [27], [28]], and mucopolysaccharide infiltration of the nasopharyngeal, oropharyngeal, hypopharyngeal, and laryngeal tissues, are typically seen in children with MPS and predispose them to upper airway obstruction [[29]]. Intrathoracic airway obstruction is also a common complication, and tracheobronchial abnormalities due to enlarged cartilage cells or soft-tissue growths can also cause narrowing of the tracheal lumen [[18]]. The trachea can be narrow, tortuous, or occluded by the accumulation of soft tissue [[29]]. Semenza et al. [[17]] also suggested alveolar and interstitial pulmonary involvement by GAG deposition. Depending on the site and severity of obstruction, patients may present with stridor, dyspnoea, retractions, cough, cyanosis, or difficulty with feeding [[26]], and the severity of respiratory dysfunction varies according to the MPS type [[29]].

Multiple abnormalities in MPS patients can reduce the ventilator capacity, manifesting as a reduction in vital capacity [[18]]. Short stature [[30]], kyphoscoliosis, and pectus carinatum are common, and diaphragm excursion may be compromised by hepatosplenomegaly [[13], [30]]. Tracheal distortion is characteristic for MPS and may reflect a disproportionate length of the trachea relative to the shortened spinal length [[31], [32]]. In combination with laxity of the tracheal tissue, it can cause airway collapse [[31]]. Cervical or lumbar spinal cord lesions may weaken expiratory muscles, impair cough, and reduce secretion clearance, predisposing patients to recurrent pneumonia. Diaphragmatic weakness may result from spinal cord compression above the phrenic nerve origin [[18]]. The combined effect of these alterations in respiratory mechanics together with airway abnormalities may lead to respiratory failure. Airway obstruction and parenchymal abnormality can impair pulmonary O2 uptake and CO2 excretion [[18]]. Ventilatory dysfunction is exacerbated by normal sleep mechanisms that increase upper airway collapsibility [[33]]. The severity of respiratory damage varies according to the MPS type [[3], [9], [17], [29], [34][38]] (Table 1). The prevalence of obstructive sleep apnoea syndrome (OSAS) is between 100% of cases as reported by Lin et al. [[14]] and 33% of MPS patients as described by Kiely et al. [[3]]. The prevalence of OSAS in patients with MPS was reported as 69.8% by Moreira et al. [[39]]. Upper airway obstruction has been described for all MPS disorders [[40]] (Table 2). Other studies in the literature report intermediate percentages [[1][3], [12][15], [41][43]] (Table 3). MPS I and MPS VI patients appear to be at the greatest risk for severe OSA [[1], [15], [42]].Table 1

Respiratory disorders in MPS patients: a review of the literature

No. of patients MPS type (n) Respiratory disorders
Kiely, 2017 [[3]] 55 MPS I RI (54.5%)Snoring (85.5%)OSA (32.7%)Laryngomalacia (9.1%)
Cohen, 2017 [[34]] 43 MPS III RI (34.88%)OSA (30.23%)T&A (34.88%)
Chiong, 2017 [[35]] 23 MPS II UAO (39%)RI (78.3%)OSA (39%)T&A (39%)
Lin, 2014 [[36]] 35 MPS I (1)MPS II (12)MPS III (4)MPS IV (16)MPS VI (6) T&A (96%)OSA (71%)Laryngomalacia (38%)
Muhlebach, 2013 [[37]] 31 MPS I (9)MPS II (19)MPS III (1)MPS IV (1)MPS VI (1) T&A (72%)Bronchomalacia (46%)Laryngomalacia (31%)
Wold, 2010 [[9]] 9 MPS I (5)MPS II (3)MPS VI (1) UAO (44.4%)
Yeung, 2009 [[29]] 27 MPS IH (8)MPS IH/S (3)MPS II (5)MPS III B (1)MPS VI (1) UAO (70%)RI (47%)
Bredenkamp, 1992 [[38]] 45 MPS IH (13)MPS II (7)MPS III (12)MPS IV (6)MPS VI (5)MPS VII (2) UAO (38%)
Semenza, 1988 [[17]] 21 MPS IH (4)MPS IH/S (3)MPS II (3)MPS IV (6)MPS VI (3)MPS VII (4) UAO (50–90%)T&A (67%)Supraglottic narrowing (92%)OSA (89%)

MPS mucopolysaccharidosis, OSA obstructive sleep apnoea, RI respiratory infection, T&A adenoid and/or tonsillar hypertrophy, UAO upper airway obstruction,

Table 2

Respiratory manifestations in classic/severe forms of MPS disorders

MPS Upper airway obstruction Lower airway obstruction Restrictive lung disease
I +++ +++ +++
II +++ +++ ++
III Minimal Minimal Minimal
IV ++ + +++
VI +++ +++ ++
VII +++ +++ ++

Data from Rapoport et al. [[40]]

MPS mucopolysaccharidosis

Table 3

Obstructive sleep apnoea (OSA) distribution and severity in each type of MPS

No. of patients MPS type (n) OSA prevalence OSA rating
Kiely, 2017 [[3]] 55 MPS I 32.7% NA
Gonuldas, 2014 [[1]] 76(only 42 studied with polysomnography) MPS I (8)MPS II (9)MPS III (23)MPS IV (13)MPS VI (21)MPS VII (2) 95% Mild (40.47%)Moderate (14.28%)Severe (40.47%)
Morimoto, 2014 [[41]] 35 MPS I (5)MPS II (25)MPS III (2)MPS IV (2)MPS VI (1) 43% NA
Kasapkara, 2014 [[42]] 19 MPS I (4)MPS II (4)MPS VI (11) 94.7% Mild (26.3%)Moderate (10.5%)Severe (57.9%)
Mesolella, 2013 [[2]] 20 MPS I (7)MPS II (6)MPS III (4)MPS IV (1)MPS VI (2) 45% NA
John, 2011 [[12]] 28 MPS VI 85.1% Mild (14.28%)Moderate (17.85%)Severe (50%)
Lin, 2010 [[14]] 24 MPS I (3)MPS II (15)MPS III (1)MPS IV (1)MPS VI (4) 100% Mild (9.1%)Moderate (31.81%)Severe (59.09%)
Nashed, 2009 [[15]] 11 MPS IH (4)MPS IH/S (2)MPS II (3)MPS IV (2) 64% Mild (9.09%)Moderate (27.27%)Severe (27.27%)
Schwartz, 2007 [[43]] 120 MPS II 48% NA
Leighton, 2001 [[13]] 26 MPS I (10)MPS II (6)MPS III (4)MPS IV (4)MPS VI (2) 92% NA

MPS mucopolysaccharidosis, NA not available

What is the possible management for respiratory disorders in MPS?

Currently, treatment of airway obstruction in patients with MPS is controversial, and has met with only moderate success [[29]]. Management of airway involvement begins with the surgical removal of the obstruction [[37]], and the accumulation of GAGs in the adenoids and tonsils, with resulting hypertrophy, makes these structures frequent targets for surgical intervention [[2]]. Therefore, MPS patients with clinical symptoms of upper airway obstruction are often subjected to adenoidectomy and/or tonsillectomy, with data reported in the literature ranging from 70 to 20% of cases [[1][3], [7], [12], [19], [29], [34], [37], [42]] (Table 4). Tonsil volume increase is also secondary to GAG deposits in the tonsillar fossa. In principle, this would make coblation intracapsular tonsillectomy not recommendable for treatment of OSA in MPS children [[38]]. Adenoidectomy and/or tonsillectomy in 35–50% of cases are performed prior to MPS diagnosis [[7], [44]]. Despite adenotonsillectomy being a routine procedure in most children, the risks are usually higher in an MPS child, including post-operative haemorrhage, airway oedema, and failure to extubate [[10]]. Therapeutically, adenoidectomy and tonsillectomy provide initial but only temporary relief of upper airway obstruction. Furthermore, the recurrence rate of adenoid hypertrophy after adenoidectomy in the MPS population is 56% [[1], [45]], while in the normal population it is between 0.55 and 1.5% [[42]]. Adenotonsillectomy alone may not be a sufficient treatment for upper airway obstruction in patients with MPS. The limited relief afforded by adenotonsillectomy is attributable to the multifactorial pathogenesis of airway obstruction and the benefit of the procedure also depends on the extent and severity of airway narrowing at other levels [[10]].Table 4

MPS and adenotonsillectomy

No. of patients MPS type (n) Surgery (%)
Cohen, 2017 [[34]] 43 MPS III T&A (23.25%)
Kiely, 2017 [[3]] 55 MPS I A (72.7%)T (61.8%)
Gonuldas, 2014 [[1]] 76 MPS I (8)MPS II (9)MPS III (23)MPS IV (13)MPS VI (21)MPS VII (2) T&A (34.21%)
Kasapkara, 2014 [[42]] 19 MPS I (4)MPS II (4)MPS VI (11) A (26.3%)T (5.3%)T&A(15.8%)
Muhlebach, 2013 [[37]] 31 MPS I (9)MPS II (19)MPS III (1)MPS IV (1)MPS VI (1) T&A (16.12%)
Mesolell, 2013 [[2]] 20 MPS I (7)MPS II (6)MPS III (4)MPS IV (1)MPS VI (2) A (15%)T (10%)T&A (25%)
Malik, 2013 [[19]] 10 MPS II T&A (70%)
John, 2011 [[12]] 28 MPS VI A (21.4%%)T&A (10.7%)
Mendelsohn, 2010 [[7]] 527 MPS II A (49.5%)T (35.5%)
Yeung, 2009 [[29]] 27 MPS IH (8)MPS IH/S (3)MPS II (5)MPS IIIB (1)MPS VI (1) T&A (70.37%)

A adenoidectomy, MPS mucopolysaccharidosis, T tonsillectomy, T&A adenotonsillectomy

When local airway procedures are no longer adequate, or when there is significant tracheobronchial involvement, non-invasive continuous positive airway pressure (CPAP) may be employed by some patients during sleep [[19]] and it is often added to the management plan [[37]]. It may provide temporary relief for some of these patients before surgical intervention, but it is generally poorly tolerated in patients with behavioural disturbance [[10]] and may become less effective as the airway disease progresses [[29]]. If patients tolerate CPAP but hypoxaemia persists, bi-level positive airway pressure (BiPAP) can be advantageous in patients with additional respiratory failure and baseline low oxygen levels.

Progression of upper airway obstruction when less invasive interventions are no longer adequate may often require a tracheotomy. Tracheotomy in MPS children may be performed to treat refractory progressive upper airway obstruction, to safeguard an anticipated difficult airway management before a planned non-ENT surgical procedure, and in emergency airway management. Yeung et al. report a rate of 11% for tracheotomy [[29]]. This rate compares with those in other studies reported in the literature [[2], [7], [12], [19], [29], [37], [38], [46]] (Table 5). Computed tomographic scan of the chest and airway is recommended prior to surgery to exclude airway narrowing distally from the carina [[26]] and multidetector computed tomography (MDCT) is suggested for pre-operative airway assessment [[47]]. MDCT images produce additional information on the glottic and subglottic structures, and airway reconstruction using MDCT derived from previous CT studies could provide a useful assessment tool in the pre-operative airway evaluation and planning of anaesthesia for MPS children. All tracheotomies in patients with MPS result in tracheotomy-related complications. Infrastomal tracheal stenosis is the most frequent complication (85.7%), and stomal narrowing (Fig. 4) also occurs frequently (71.4%) after each tracheotomy [[46]]. Granulation formation and wound infection are described [[18]]. These complications cause difficult cannula care, with a high frequency of surgery revisions. Airway problems may persist after tracheotomy due to persistent airway collapse distal to the tip of the endotracheal tube [[21]], and tracheobronchial stents may be useful [[48], [49]].Table 5

MPS and tracheotomy

No. of patients MPS type (n) Tracheotomy (%)
Muhlebach, 2013 [[37]] 31 MPS I (9)MPS II (19)MPS III (1)MPS IV (1)MPS VI (1) 19.35%
Mesolella, 2013 [[2]] 20 MPS I (7)MPS II (6)MPS III (4)MPS IV (1)MPS VI (2) 5%
Malik, 2013 [[19]] 10 MPS II 100%Complications:Granulation (40%)Wound infection (30%)Ulceration (10%)
John, 2011 [[12]] 28 MPS VI 3.6%
Mendelsohn, 2010 [[7]] 527 MPS II 4.4%
Yeung, 2009 [[29]] 27 MPS IH (8)MPS IH/S (3)MPS II (5)MPS III B (1)MPS VI (1) 11%
Jeong, 2006 [[46]] 3 MPS II 100%Complications:Stomal narrowing (71.4%)Granulation (57.1%)Wound infection (28.6%)Infrastomal stenosis (85.7%)
Bredenkamp, 1992 [[38]] 45 MPS IH (13)MPS II (7)MPS III (12)MPS IV (6)MPS VI (5)MPS VII (2) 16%

MPS mucopolysaccharidosis

Fig. 4

Stomal narrowing

Is hearing loss an important symptom for the diagnosis of MPS?

Hearing loss is almost a universal finding in children with MPS [[29], [50], [51]]. From the hearing standpoint, it is very common to find conductive hearing loss. However, many patients present a sensorineural component [[52]]. The conductive component of hearing loss is attributed to the presence of seromucinous otitis (Fig. 5) or bone chain deformities [[53]], disruption in ossicular conduction by histopathological anomalies similar to otosclerosis, or by arthropathy [[54]]. Sensorineural hearing loss (SHL) is thought to be caused by the accumulation of GAGs in the cochlea, auditory nerve, and brain stem. Auditory pathophysiology in the central nervous system in Hurler syndrome remains unknown [[55]]; however, decreased cochlear hair cells may be one of the important factors for the sensorineural component of hearing loss. In many patients, mixed-type hearing loss can also be seen. In MPS II (Hunter syndrome), the most prevalent otolaryngological manifestations and interventions reported are otitis (either acute otitis media or chronic otitis media [72%]), hearing loss (67%), insertion of ventilation tubes (50%), adenoidectomy (47%), and hearing aids (41%) [[5]]. Tables 6 and 7 describe the different audiological findings in subtypes of MPS [[52], [56]].Fig. 5

Middle ear effusion

Table 6

Audiological findings in subtypes of MPS

Sign/symptom MPS I MPS II MPS III MPS IV MPS VI MPS VII
Hearing loss ++ ++ + + ++ ++
Recurrent ear infections ++ ++ + + ++ ++

MPS mucopolysaccharidosis

++ exhibited by majority of patients with diagnosis, + exhibited by some patients with diagnosis

Table 7

Audiometrical findings of patients with MPS

Patient Age (years) Diagnosis Tympanometrical findings Type of hearing loss Degree of hearing loss
Right Left Right Left Right Left
1 9 MPS VI Type C Type A Conductive Conductive Slight Mild
2 4 MPS VI Type C Type C Mixed Mixed Moderate Moderate
3 3 MPS I Type B Type B Mixed Mixed Severe Severe
4 3 MPS I Type B Type B Mixed Mixed Severe Severe
5 9 MPS VI Type B Type B Conductive Conductive Moderate Moderately severe
6 8 MPS IV Type B Type B Mixed Mixed Moderate Mild
7 6 MPS I Type B Type B Conductive Conductive Moderate Moderately severe
8 7 MPS IV Type B Type B Mixed Mixed Moderate Moderate
9 2 MPS III Type B Type B Mixed Mixed Severe Profound

MPS mucopolysaccharidosis

Are these signs typical of early-onset MPS?

Early recognition of MPS requires careful attention to the presence of multiple signs and symptoms, many of which overlap with common childhood complaints. Children with MPS have a high risk of hearing loss and this is an early symptom. Thus, early otolaryngological evaluation and intervention are recommended [[56]]. Clinical suspicion of the disease can be triggered by particular clusters of signs and symptoms that are unlikely to appear in an unaffected child but that often occur together in the child with MPS II (Table 8).Table 8

“Red flag” signs and symptoms of MPS II that occur early in the disease course

Coarse facial features (may be subtle in the attenuated phenotype)
Recurrent respiratory infections
Chronic rhinorrhoea
Upper airway restriction/noisy breathing/snoring
Recurrent otitis media
Hearing loss
Heart murmur
Hepatomegaly
Umbilical and inguinal hernia
Recurrent watery diarrhoea
Joint stiffness
Developmental delay and/or speech delay (in severe phenotype only)

MPS mucopolysaccharidosis

What is the therapeutic treatment for these audiological-otologic findings?

Sensorineural or mixed conductive and sensorineural hearing loss commonly develop in Morquio A patients in the first decade of life [[57]]. Conductive hearing loss due to retained middle ear fluid can be treated using ventilation tubes. Long-lasting types of tympanostomy tubes (Fig. 6) are preferable for use on the first occasion considering the anaesthetic risks and the risk of the re-occurrence of the middle ear fluid. Post-aural hearing aids may be most appropriate if a progressive neurosensory element to hearing loss is present. However, despite hearing normalisation after placement of transtympanic drainage tubes, this does not exempt such patients from a periodic audiological follow-up [[51], [58]]. Both amplification with hearing aids and transtympanic ventilation tubes appear to be effective in improving language development in children with moderate cognitive impairment [[59]]. Periodic follow-up of these patients is mandatory because of hearing impairment and consequences for their development and quality of life.Fig. 6

Ventilation tube

Conclusion

MPS are rare, progressive, and multisystem diseases with insidious signs and symptoms. Various ENT manifestations appear in the early stage of MPS, including otitis media, macroglossia, adenotonsillar hypertrophy, nasal obstruction, OSAS, progressive respiratory disorders, and hearing loss. As the incidence of hearing loss is high in MPS patients, hearing loss should be determined at an early stage. After the diagnosis, the required treatments should be started promptly with the aim of increasing the quality of life. However, it has to be considered that this is only possible as a result of regular and systematic follow-up. Respiratory disorders occur in all types of MPS. The respiratory involvement is usually progressive and can result in morbidity and mortality early in childhood [[10], [26]]. MPS patients with clinical symptoms of upper airway obstruction often undergo adenoidectomy and/or tonsillectomy (20–70% of cases). Adenoidectomy and/or tonsillectomy in 35–50% of cases are performed prior to MPS diagnosis [[7], [44]]. Progression of upper airway obstruction when less invasive interventions are no longer adequate may often require a tracheotomy. All tracheotomies in patients with MPS result in tracheotomy-related complications.

Undiagnosed MPS patients are frequently referred to otolaryngologists because of their early onset of ENT manifestations, before the diagnosis of MPS is confirmed. Otolaryngologists thus have an early opportunity to recognize MPS and they can play an increasingly integral role in the multidisciplinary approach to the diagnosis and management of many children with MPS. The ENT commitment is therefore to suspect MPS when non-specific ENT pathologies are associated with repeated surgical treatments, unexplainable worsening of diseases despite correct treatment, and with signs, symptoms, and pathological conditions such as hepatomegaly, inguinal hernia, macrocephaly, macroglossia, coarse facial features, hydrocephalous, joint stiffness, bone deformities, valvular cardiomyopathy, carpal tunnel syndrome, and posture and visual disorders. Prompt diagnosis may also help avoid complications during surgical intervention. Patients with MPS submitted to surgery may experience difficulty or complications with all kinds of surgical procedures, possibly leading to emergency tracheotomy or even death. If a patient is recognized pre-operatively to have MPS, a well-prepared team of anaesthesiologists and surgeons can be primed for any surgical intervention required and they will know to use specific surgical and intubation/extubation techniques that are recommended for patients with MPS [[60]].

Therefore, we suggest that otolaryngologists should consider MPS for an early detection of a possible MPS-affected child when collecting the medical history of all children, and especially those being sent to an ENT specialist earlier than usual (at 2–3 years of age) for adenotonsillectomy. The possible association with recurrent otitis media with effusion, inguinal or umbilical hernia, adenotonsillar hypertrophy, sensorineural/conductive hearing loss, OSAS, worsening respiratory obstruction, and bone/joint anomalies should be emphasised. Future studies should consider the use of sleep disordered breathing as an objective parameter of clinical and metabolic improvement [[61]].

Acknowledgements

Funding

The publication costs for this paper in the IJP supplement were made possible with unconditional financial support from BioMarin, Sanofi Genzyme, and Shire. The sponsors had no input into the content of articles, which were independently prepared by the authors and have undergone the journal’s standard peer-review process.

About this supplement

This article has been published as part of Italian Journal of Pediatrics, Volume 44 Supplement 2, 2018: Mucopolysaccharidoses: state of the art. The full contents of the supplement are available online at https://ijponline.biomedcentral.com/articles/supplements/volume-44-supplement-2.

References

  1. B¸ GonuldasT YılmazSH SivriKS GucerK KılıncGA GencMucopolysaccharidosis: otolaryngologic findings, obstructive sleep apnea and accumulation of glucosaminoglycans in lymphatic tissue of the upper airwayInt J Pediatr Otorhinolaryngol20147894494910.1016/j.ijporl.2014.03.02124731921
  2. M MesolellaM CimminoE CantoneA MarinoM CozzolinoR Della CasaManagement of otolaryngological manifestations in mucopolysaccharidoses: our experienceActa Otorhinolaryngol Ital20133326727224043915
  3. BT KielyJL KohlerHY ColettiMD PoeML EscolarEarly disease progression of hurler syndromeOrphanet J Rare Dis2017123210.1186/s13023-017-0583-728193245
  4. B GuffonB HeronB ChabrolF FeilletV MontaubanV ValayannopoulosDiagnosis, quality of life, and treatment of patients with hunter syndrome in the French healthcare system: a retrospective observational studyOrphanet J Rare Dis2015104310.1186/s13023-015-0259-025887606
  5. A KeilmannTN IainA BruceD MolteG MalmHearing loss in patients with mucopolysaccharidosis II: data from HOS—the hunter outcome surveyJ Inherit Metab Dis20123534335310.1007/s10545-011-9378-521866356
  6. M ScarpaZ AlmássyM BeckO BodamerIA BruceL De MeirleirMucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare diseaseOrphanet J Rare Dis201167210.1186/1750-1172-6-7222059643
  7. NJ MendelsohnP HarmatzO BodamerBK BurtonR GiuglianiSA JonesImportance of surgical history in diagnosing mucopolysaccharidosis type II (hunter syndrome): data from the hunter outcome surveyGenet Med20101281682210.1097/GIM.0b013e3181f6e74d21045710
  8. JE WraithM BeckR GiuglianiJ ClarkeR MartinJ MuenzerHOS InvestigatorsInitial report from the hunter outcome surveyGenet Med20081050851610.1097/GIM.0b013e31817701e618580692
  9. SM WoldCS DerkayDH DarrowV ProudRole of the pediatric otolaryngologist in diagnosis and management of children with mucopolysaccharidosesInt J Pediatr Otorhinolaryngol201074273110.1016/j.ijporl.2009.09.04219931921
  10. MS MuhlebachW WootenJ MuenzerRespiratory manifestations in mucopolysaccharidosesPaediatr Resp Rev20111213313810.1016/j.prrv.2010.10.005
  11. P ArnA BruceJE WraithH TraversS FalletAirway-related symptoms and surgeries in patients with mucopolysaccharidosisAnn Otol Rhinol Laryngol201512419820510.1177/000348941455015425214650
  12. A JohnS FagondesI SchwartzAC AzevedoP BarriosP DalcinSleep abnormalities in untreated patients with mucopolysaccharidosis type VIAm J Med Genet Part A20111551546155110.1002/ajmg.a.33902
  13. SEJ LeightonB PapsinA VellodiR DinwiddieR LaneDisordered breathing during sleep in patients with mucopolysaccharidosesInt J Pediatr Otorhinolaryngol20015812713810.1016/S0165-5876(01)00417-711278021
  14. HY LinMR ChenCC LinCP ChenDS LinCK ChuangPolysomnographic characteristics in patients with mucopolysaccharidosesPediatr Pulmonol2010451205121210.1002/ppul.2130920717914
  15. A NashedS Al-SalehJ GibbonsI MacLuskyJ MacFarlaneA RiekstinsSleep-related breathing in children with mucopolysaccharidosisJ Inherit Metab Dis20093254455010.1007/s10545-009-1170-419562504
  16. F SantamariaMV AndreucciG ParentiM PolverinoD ViggianoS MontellaUpper airway obstructive disease in mucopolysaccharidoses: polysomnography, computed tomography and nasal endoscopy findingsJ Inherit Metab Dis20073074374910.1007/s10545-007-0555-517570075
  17. GL SemenzaRE PyeritzRespiratory complications of mucopolysaccharide storage disordersMedicine19886720921910.1097/00005792-198807000-000023134589
  18. KI BergerFC FagondesR GiuglianiKA HardyK Sheng LeeC McArdleRespiratory and sleep disorders in mucopolysaccharidosisJ Inherit Metab Dis20133620121010.1007/s10545-012-9555-123151682
  19. V MalikJ NichaniMP RotheraJE WraithSA JonesR WalkerIA BruceTracheostomy in mucopolysaccharidosis type II (Hunter’s syndrome)Int J Pediatr Otorhinolaryngol2013271204120810.1016/j.ijporl.2013.05.002
  20. R NaganoS TakizawaN HayamaS UmemuraT UesugiS NakagawaThree-dimensional CT and histopathological findings of airway malacia in hunter syndromeTokai J Exp Clin Med200732596121319059
  21. CJ PelleyJ KwoDR HessTracheomalacia in an adult with respiratory failure and Morquio syndromeRespir Care20075227828217328826
  22. Shih S.-L.Lee Y.-J.Lin S.-P.Sheu C.-Y.J.G. BlickmanAirway changes in children with mucopolysaccharidoses: CT evaluationActa Radiologica2002431404310.1080/02841850212734762811972460
  23. HS SimsJJ KempinersSpecial airway concerns in patients with mucopolysaccharidosesRespir Med20071011779178210.1016/j.rmed.2007.02.01317412578
  24. MA SimmonsIA BruceS PenneyE WraithMP RotheraOtorhinolaryngological manifestations of the mucopolysaccharidosesInt J Pediatr Otorhinolaryngol20056958959510.1016/j.ijporl.2005.01.01715850680
  25. J ShapiroM StromeAC CrockerAirway obstruction and sleep apnea in hurler and hunter syndromesAnn Otol Rhinol Laryngol19859445846110.1177/0003489485094005083931528
  26. SY ShinharH ZablockiDN MadgyAirway management in mucopolysaccharide storage disordersArch Otolaryngol Head Neck Surg200413023323710.1001/archotol.130.2.23314967758
  27. R PariniM RigoldiL TedescoL BoffiA BrambillaS BertolettiEnzymatic replacement therapy for hunter disease: up to 9 years experience with 17 patientsMol Genet Metab Rep20153657410.1016/j.ymgmr.2015.03.01126937399
  28. R PariniSA JonesPR HarmatzR GiuglianiNJ MendelsohnThe natural history of growth in patients with hunter syndrome: data from the hunter outcome survey (HOS)Mol Genet Metab201611743844610.1016/j.ymgme.2016.01.00926846156
  29. AH YeungMJ CowanB HornKW RosbeAirway management in children with mucopolysaccharidosesArch Otolaryngol Head Neck Surg2009135737910.1001/archoto.2008.51519153310
  30. R GiuglianiP HarmatzJE WraithManagement guidelines for mucopolysaccharidosis VIPediatrics200712040741810.1542/peds.2006-2184
  31. R WalkerKG BelaniEA BraunlinIA BruceH HackPR HarmatzAnaesthesia and airway management in mucopolysaccharidosisJ Inherit Metab Dis20133621121910.1007/s10545-012-9563-123197104
  32. R ReichertLG CamposF VairoCF de SouzaJA PérezJÁ DuarteNeuroimaging findings in patients with mucopolysaccharidosis: what you really need to knowRadiographics2016361448146210.1148/rg.201615016827618324
  33. JA DempseySC VeaseyBJ MorganCP O’DonnellPathophysiology of sleep apneaPhysiol Rev2010904711210.1152/physrev.00043.200820086074
  34. MA CohenGM StuartDelivery of anesthesia for children with mucopolysaccharidosis type III (Sanfilippo syndrome): a review of 86 anestheticsPediatr Anesth20172736336910.1111/pan.13075
  35. MA ChiongDM CansonMAR AbacanMMP BaluyotCP CorderoCL SilaoClinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II—hunter syndromeOrphanet J Rare Dis20171271810.1186/s13023-016-0558-028077157
  36. SP LinSC ShihCK ChuangKS LeeMR ChenDM NiuCharacterization of pulmonary function impairments in patients with mucopolysaccharidoses—changes with age and treatmentPediatr Pulmonol20144927728410.1002/ppul.2277423401495
  37. MS MuhlebachCD ShafferL GeorgesK AbodeJ MuenzerBronchoscopy and airway management in patients with mucopolysaccharidoses (MPS)Pediatr Pulmonol20134860160710.1002/ppul.2262922949390
  38. JK BredenkampME SmithJP DudleyJC WilliamsRL CrumleyDM CrockettOtolaryngologic manifestations of mucopolysaccharidosesAnn Otol Rhinol Laryngol199210147247810.1177/0003489492101006051610064
  39. GA MoreiraS KyosenC PattiAM MartinsS TufikPrevalence of obstructive sleep apnea in patients with mucopolysaccharidosis types I, II, and VI in a reference centerSleep Breath20141879179710.1007/s11325-014-0944-624705807
  40. D RapoportJ MitchellPathophysiology, evaluation, and management of sleep disorders in the mucopolysaccharidosesMol Genet Metab2017122495410.1016/j.ymgme.2017.08.008
  41. N MorimotoM KitamuraM KosugaT OkuyamaCT and endoscopic evaluation of larynx and trachea in mucopolysaccharidosesMol Genet Metab201411215415910.1016/j.ymgme.2014.03.01324767144
  42. CS KasapkaraL TümerAT AslanA HasanoğluFS EzgüA KüçükçongarHome sleep study characteristics in patients with mucopolysaccharidosisSleep Breath20141814314910.1007/s11325-013-0862-z23690022
  43. I SchwartzMG RibeiroJG MotaMB TorallesP CorreiaD HorovitzA clinical study of 77 patients with mucopolysaccharidosis type IIActa Paediatr200796637010.1111/j.1651-2227.2007.00212.x17391446
  44. A KeilmannAK LassigA Pollak-HainzWJ MannM BeckM HainzAdenoids of patients with mucopolysaccharidoses demonstrate typical alterationsInt J Pediatr Otorhinolaryngol20157911511810.1016/j.ijporl.2014.11.01425487873
  45. A MonroyP BeharL BrodskyRevision adenoidectomy—a retrospective studyInt J Pediatr Otorhinolaryngol20087256557010.1016/j.ijporl.2008.01.00818295352
  46. HS JeongDY ChoKM AhnDK JinComplications of tracheotomy in patients with mucopolysaccharidoses type II (hunter syndrome)Int J Pediatr Otorhinolaryngol2006701765176910.1016/j.ijporl.2006.05.02116831472
  47. PM IngelmoR PariniM GrimaldiF MauriM RomagnoliG TagliabueMultidetector computed tomography (MDCT) for preoperative airway assessment in children with mucopolysaccharidosesMin Anestesiol201177774780
  48. M RuttenP CietR van den BiggelaarE OussorenJL LangendonkAT van der PloegM LangeveldSevere tracheal and bronchial collapse in adults with type II mucopolysaccharidosisOrphanet J Rare Dis2016115010.1186/s13023-016-0425-z27112191
  49. R KarlS CarolaE ReginaN ThomasRM HuberTracheobronchial stents in mucopolysaccharidosisInt J Pediatr Otorhinolaryngol20168318719210.1016/j.ijporl.2016.02.01526968075
  50. S SantosL LópezL GonzálezJ DomínguezaHearing loss and airway problems in children with mucopolysaccharidosesActa Otorrinolaringol Esp20116241141710.1016/j.otorri.2011.05.00321757178
  51. M MotamedS ThorneA NarulaTreatment of otitis media with effusion in children with mucopolysaccharidosesInt J Pediatr Otorhinolaryngol20005312112410.1016/S0165-5876(00)00320-710906517
  52. C GökdoğanS AltinyayTH GökdoganB GündüzI OkurAudiologic evaluations of children with mucopolysaccharidosisBraz J Otorhinolaryngol20168228128410.1016/j.bjorl.2015.05.00726601996
  53. G ZechnerM MoserOtosclerosis and mucopolysaccharidosisActa Otolaryngol19871033843863113169
  54. Netzloff ML, Elsea SH, Fisher RA. Genetic hearing loss associated with metabolic disorders. In: Toriello, Reardon, Gorlin (eds). Hereditary hearing loss and its syndromes. 2nd ed. Oxford University Press; 2004:387–392.
  55. S KariyaInner ear changes in mucopolysaccharidosis type I/Hurler syndromeOtol Neurotol201231323132710.1097/MAO.0b013e3182659cc3
  56. BK BurtonR GiulianiDiagnosing hunter syndrome in pediatric practice: practical considerations and common pitfallsEur J Pediatr201217163163910.1007/s00431-012-1703-y22383073
  57. CJ HendrikszKI BergerR GiuglianiP HarmatzC KampmannWG MackenzieInternational guidelines for the management and treatment of Morquio a syndromeAm J Med Genet2015167112510.1002/ajmg.a.36833
  58. YS ChoJH KimTW KimSC ChungSA ChangDK JinOtologic manifestations of hunter syndrome and their relationship with speech developmentAudiol Neuro Otol20081320621210.1159/000113511
  59. MF Vargas-GamarraAudiological findings in children with mucopolysaccharidoses type I–IVActa Otorrinolaringol Esp2017163013030133
  60. RW WalkerM DarowskiP MorrisJE WraithAnaesthesia and mucopolysaccharidoses. A review of airway problems in childrenAnaesthesia1994491078108410.1111/j.1365-2044.1994.tb04360.x7864325
  61. A PalE LangereisM SaifJ MercerH ChurchK TyleeSleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcomeOrphanet J Rare Dis2015104210.1186/s13023-015-0255-425887468
The underlying source XML for this text is taken from https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6238253/fullTextXML. The license for the article is Creative Commons Attribution 4.0 International. The main subject has been identified as mucopolysaccharidosis.